Psomagen (XKRX:950200) Other Financing: ₩0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKRX:950200 Psomagen Inc XKRX:950200
72 GF Score
Price ₩3,230.00
GF Value ₩5,268.78
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Psomagen Other Financing?

Psomagen XKRX:950200 -1.22% 72 Other Financing is ₩0 Mil as of Jun. 2026. GuruFocus rates XKRX:950200 with a GF Score™ of 72/100 and a GF Value™ of ₩5,268.78 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Psomagen's Other Financing for the three months ended in Jun. 2026 was ₩0 Mil.

Psomagen's Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 was ₩0 Mil.

Psomagen Other Financing Historical Data

* Premium members only.

The historical data trend for Psomagen's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Psomagen Other Financing Chart

Psomagen Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial -12.57 -10.60 123.34 138.93 -0.00

Psomagen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 0.00 -0.00 0.00 0.00
XKRX:950200
72GF Score
Psomagen Inc XKRX:950200
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Psomagen Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of ₩0 Mil mean?
Psomagen (XKRX:950200) has a Other Financing of ₩0 Mil as of Jun. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Psomagen and its competitors.
Is Psomagen's Other Financing too high?
Psomagen's current Other Financing is ₩0 Mil. Overall, Psomagen has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Psomagen's Other Financing compare to TMO and DHR?
Psomagen's Other Financing of ₩0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Diagnostics & Research company?
A good Other Financing depends on the Medical Diagnostics & Research industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Psomagen and its competitors. Psomagen's current Other Financing is ₩0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Psomagen stock overvalued right now?
Based on GuruFocus' analysis, Psomagen (XKRX:950200) is currently considered Significantly Undervalued. The stock's GF Value™ is ₩5,268.78, compared to a current price of ₩3,230.00 — trading 38.7% below its estimated fair value. The current Other Financing is ₩0 Mil. Psomagen's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Psomagen (XKRX:950200), the current Other Financing is ₩0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Psomagen (XKRX:950200) Overvalued in 2026?

Based on GuruFocus' analysis, Psomagen stock appears to be undervalued. The current stock price of ₩3,230.00 is trading 38.7% below its estimated GF Value™ of ₩5,268.78. GuruFocus considers Psomagen to be Significantly Undervalued.

Key valuation signals for XKRX:950200:

  • Other Financing: ₩0 Mil
  • GF Value™: ₩5,268.78 vs. price of ₩3,230.00 (38.7% below fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the XKRX:950200 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Psomagen Business Description

Address 1330 Piccard Drive, Suite 103, Rockville, MD, USA, 20850
Psomagen Inc provides total genomic solutions for both clinical and research purposes. It is mainly focused on end-to-end sequencing services. The company also offers services such as personal DNA tests, clinical sequencing, research sequencing, and others.
72GF Score

Get the complete analysis for XKRX:950200

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₩3,230.00
Price
₩5,268.78
GF Value